Ozmosi | Propantheline bromide Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Propantheline bromide

Alternative Names: propantheline bromide, pro-banthine
Clinical Status: Inactive
Latest Update: 2012-07-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: mAChR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | China | India | Ireland | New Zealand | Pakistan | Taiwan | Turkey | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title